Navigation Links
OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
Date:8/10/2009

BOTHELL, WA, and VANCOUVER, Aug. 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers. The patent, licensed from The University of British Columbia, includes coverage for the method for treating cancers that express the protein clusterin using OGX-011, or any other clusterin antisense oligonucleotide, in combination with any chemotherapeutic agent or radiation therapy.

"The issuance of this patent expands our intellectual property estate for treating clusterin-expressing cancers using antisense therapy and provides us with a broad patent that applies well beyond prostate cancer," said Scott Cormack, President and CEO of OncoGenex. "Importantly, given that our current Phase 3 plans include combining OGX-011 with chemotherapy, this patent directly relates to our current method of using OGX-011."

OncoGenex Pharmaceuticals, Inc. owns or has licenses to approximately 67 granted or issued U.S. and foreign patents, and approximately 140 pending U.S. and foreign patent applications worldwide. Composition of matter patents covering OGX-011, OGX-427, SN2310, CSP-9222 and TOCOSOL(TM) have issued in the U.S. and certain other jurisdictions. Additional patent applications covering all of these products, as well as other technologies, are pending in the U.S. and certain other countries. TRPM-2 is an historical name for clusterin, and survives in some of the earlier patent filings.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by The University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the scope of the claims in our issued patents, the nature and extent of our intellectual property, the benefits provided by such issued patents and intellectual property and our plans with respect to our clinical development activities. Such forward-looking statements are subject to risks and uncertainties, including, among others: the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Reports Second Quarter 2009 Financial Results
2. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
3. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
4. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
5. OncoGenex Pharmaceuticals Added to Russell Indexes
6. OncoGenex Pharmaceuticals Files Shelf Registration Statement
7. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
10. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
11. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):